Advertisement
Advertisement

HIV Care Today


Why the Proposed Massachusetts HIV Testing Bill Is Bad for Patients
By Paul E. Sax, M.D.
August 9, 2011

First, there's the requirement for written informed consent, something that every state (except a couple) has wisely abandoned. Second, it's more than a testing law -- it's also an HIV privacy law, which is arguably unnecessary in this post HIPAA era and has all sorts of unintended consequences.

Read more …


Really Rapid Review -- IAS 2011 Rome
By Paul E. Sax, M.D.
July 28, 2011

Just back from IAS 2011 (which was followed, I'm thrilled to say, with a visit to perhaps the most beautiful region in the world). Here is a Really Rapid ReviewTM of the meeting, with apologies ahead of time for lack of organization and (even more likely) leaving out something important. FYI, the abstracts are online here; I'm sure there's a place on the meeting homepage that has the same link, but I can't seem to find it.

Read more …


Should HIV Meds for HIV-Uninfected People Be a Priority? And Other PrEP Questions
By Jeannie Wraight
July 21, 2011

Groundbreaking results of two large pre-exposure prophylaxis (PrEP) studies may lead to a new prevention option to reduce HIV transmission. Data released on two PrEP studies showed high levels of protection against HIV infection when tenofovir (Viread) or Truvada (tenofovir and emtricitabine) were taken daily by HIV-uninfected individuals at high risk for infection.

Read more …


Keeping Up With Erectile Dysfunction: Why Are There So Many Men Over 50 Asking for Help?
By Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
July 18, 2011

In my current practice, every day there is at least one man over the age of 50 asking for an erectile dysfunction (ED) medication. It seems to have become an epidemic. Or it is just more openly discussed. Or both.

Read more …


More Favorable Results on PrEP, But ...
By Paul E. Sax, M.D.
July 14, 2011

As part of the usual flurry of studies released just before major scientific meetings, results of two pre-exposure prophylaxis (PrEP) trials in heterosexual men and women have just been made public:

Read more …


A Thank You to Nice Patients
By Paul E. Sax, M.D.
July 12, 2011

The result of the above stellar behavior? I would do virtually anything to try and help her. Back in the late 1990s, when she was very sick with AIDS, one of my fellows said it best: "There's just something about her that makes you want to take care of her." Exactly.

Read more …


The HIV/AIDS Spectrum Project: Building Capacity to Improve Care for Mental Health and Substance Use
By David Fawcett, Ph.D., L.C.S.W.
July 12, 2011

It was the peak time for the cherry blossoms in Washington, D.C. -- or so I was told. I only caught a glimpse of them from the Metro as I was riding in from Reagan National, and a few times out the window of the hotel conference room (along with rain and even a brief burst of hail during that tempestuous spring weekend). But I wasn't in town for sightseeing: I was one of about 15 individuals from around the country selected to participate in the Training of Trainers program, a component of the National Association of Social Workers' HIV/AIDS Spectrum: Mental Health Training and Education of Social Workers Project.

Read more …


New Viral Load Technologies: Potential for a Real-Time Virologic Mess
By Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
July 7, 2011

A while back, after a challenging day in the office, I came home to the pleasure of reading the Winter 2011 edition of HIV Specialist, the magazine of the American Academy of HIV Medicine (AAHIVM). Of particular interest to my weary brain was an article by Bruce J. Packett II entitled "The Evolution of Viral Load Technologies."

Read more …


How You Can Help Your Patients Who Are Running Out of HIV Treatment Options
By Nelson Vergel, B.S.Ch.E., M.B.A.
July 6, 2011

Of the HIV medications in development with potential activity against highly resistant HIV (i.e., patients with GSS=0), two may become available within the next year: ibalizumab (formerly TNX-355), a monoclonal antibody currently under development by TaiMed Biologics, and dolutegravir (formerly GSK1349572), a second-generation integrase inhibitor made by ViiV Healthcare).

Read more …


Abacavir Agonistes
By Paul E. Sax, M.D.
June 24, 2011

The studies on abacavir and its potential association with increased cardiovascular risk have been inconsistent ever since the news first broke at CROI 2008. But recently the data have been swirling around so fast and furious that it seems appropriate to take out this famous Greek epithet.

Read more …

 < Prev  |  1  |  …  |  10  |  11  |  12  |  13  |  14  |  15  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement